Judge denies AstraZeneca’s request for exclusivity to sell blockbuster cholesterol medication
A federal judge refused AstraZeneca’s request to temporarily ban companies from selling generic versions of rosuvastatin calcium (Crestor), Bloomberg reports. Barring an appeal, companies will be able to sell cheaper versions of the blockbuster medication, which accounted for more than $5 billion in sales.
On May 31, AstraZeneca filed an appeal asking the FDA for extended patent exclusivity for the drug, which is used to lower blood cholesterol. If the appeal fails, Bloomberg projects sales of rosuvastatin calcium would decrease to $3.5 billion this year.
Read the full article below:
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.